{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:17:05Z","timestamp":1788369425239,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Splicing factor 3B subunit 1 (SF3B1) is the largest component of SF3b protein complex which is involved in the pre-mRNA splicing mechanism. Somatic mutations of SF3B1 were shown to be associated with aberrant splicing, producing abnormal transcripts that drive cancer development and\/or prognosis. In this study, we focus on the relationship between SF3B1 and four types of cancer, namely myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL) and breast cancer (BC). For this purpose, we identified from the Pubmed library only articles which mentioned SF3B1 in connection with the investigated types of cancer for the period 2007 to 2018 to reveal how the connection has developed over time. We left out all published articles which mentioned SF3B1 in other contexts. We retrieved the target articles and investigated the association between SF3B1 and the mentioned four types of cancer. For this we utilized some of the publicly available databases to retrieve gene\/variant\/disease information related to SF3B1. We used the outcome to derive and analyze a variety of complex networks that reflect the correlation between the considered diseases and variants associated with SF3B1. The results achieved based on the analyzed articles and reported in this article illustrated that SF3B1 is associated with hematologic malignancies, such as MDS, AML, and CLL more than BC. We found that different gene networks may be required for investigating the impact of mutant splicing factors on cancer development based on the target cancer type. Additionally, based on the literature analyzed in this study, we highlighted and summarized what other researchers have reported as the set of genes and cellular pathways that are affected by aberrant splicing in cancerous cells.<\/jats:p>","DOI":"10.1038\/s41598-023-29777-5","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T06:55:14Z","timestamp":1676962514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Studying the connection between SF3B1 and four types of cancer by analyzing networks constructed based on published research"],"prefix":"10.1038","volume":"13","author":[{"given":"Asmaa","family":"Samy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Kemal","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Alhajj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"29777_CR1","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/S0140-6736(05)67725-2","volume":"366","author":"G Danaei","year":"2005","unstructured":"Danaei, G. et al. Causes of cancer in the world: Comparative risk assessment of nine behavioural and environmental risk factors. Lancet 366, 1784\u20131793 (2005).","journal-title":"Lancet"},{"key":"29777_CR2","doi-asserted-by":"publisher","unstructured":"Reagan, M. Causes of cancer: Genetic, epigenetic, viral, microenvironmental, and environmental contributions to cancer. In Cancer: Prevention, Early Detection, Treatment and Recovery 2nd edn, (eds Stein, G.S. & Luebbers, K.P.) pp.53\u201374. https:\/\/doi.org\/10.1002\/9781119645214.ch3 (Wiley Publisher, 2019).","DOI":"10.1002\/9781119645214.ch3"},{"key":"29777_CR3","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1038\/leu.2016.149","volume":"30","author":"H Dolatshad","year":"2016","unstructured":"Dolatshad, H. et al. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes. Leukemia 30, 2322 (2016).","journal-title":"Leukemia"},{"key":"29777_CR4","doi-asserted-by":"publisher","first-page":"10615","DOI":"10.1038\/ncomms10615","volume":"7","author":"S Alsafadi","year":"2016","unstructured":"Alsafadi, S. et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat. Commun. 7, 10615 (2016).","journal-title":"Nat. Commun."},{"key":"29777_CR5","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.celrep.2015.09.053","volume":"13","author":"RB Darman","year":"2015","unstructured":"Darman, R. B. et al. Cancer-associated SF3B1 hotspot mutations induce cryptic 3\u2032 splice site selection through use of a different branch point. Cell Rep. 13, 1033\u20131045 (2015).","journal-title":"Cell Rep."},{"key":"29777_CR6","doi-asserted-by":"publisher","first-page":"e1004105","DOI":"10.1371\/journal.pcbi.1004105","volume":"11","author":"C DeBoever","year":"2015","unstructured":"DeBoever, C. et al. Transcriptome sequencing reveals potential mechanism of cryptic 3\u2032 splice site selection in SF3B1-mutated cancers. PLoS Comput. Biol. 11, e1004105 (2015).","journal-title":"PLoS Comput. Biol."},{"key":"29777_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41418-018-0231-3","volume":"26","author":"C Di","year":"2019","unstructured":"Di, C. et al. Function, clinical application, and strategies of Pre-mRNA splicing in cancer. Cell Death Differ. 26, 1181\u20131194 (2019).","journal-title":"Cell Death Differ."},{"key":"29777_CR8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"29777_CR9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.cell.2009.02.009","volume":"136","author":"MC Wahl","year":"2009","unstructured":"Wahl, M. C., Will, C. L. & L\u00fchrmann, R. The spliceosome: Design principles of a dynamic RNP machine. Cell 136, 701\u2013718 (2009).","journal-title":"Cell"},{"key":"29777_CR10","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.1093\/emboj\/cdf480","volume":"21","author":"CL Will","year":"2002","unstructured":"Will, C. L. et al. Characterization of novel SF3b and 17S U2 snRNP proteins, including a human Prp5p homologue and an SF3b DEAD-box protein. EMBO J. 21, 4978\u20134988 (2002).","journal-title":"EMBO J."},{"key":"29777_CR11","doi-asserted-by":"publisher","first-page":"10092","DOI":"10.1021\/bi060429o","volume":"45","author":"DM Cass","year":"2006","unstructured":"Cass, D. M. & Berglund, J. A. The SF3b155 n-terminal domain is a scaffold important for splicing. Biochemistry 45, 10092\u201310101 (2006).","journal-title":"Biochemistry"},{"key":"29777_CR12","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1101\/gad.12.10.1409","volume":"12","author":"C Wang","year":"1998","unstructured":"Wang, C. et al. Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. Genes Dev. 12, 1409\u20131414 (1998).","journal-title":"Genes Dev."},{"key":"29777_CR13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.molcel.2016.08.036","volume":"64","author":"C Cretu","year":"2016","unstructured":"Cretu, C. et al. Molecular architecture of SF3b and structural consequences of its cancer-related mutations. Mol. Cell 64, 307\u2013319 (2016).","journal-title":"Mol. Cell"},{"key":"29777_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/wrna.1222","volume":"5","author":"K Yoshida","year":"2014","unstructured":"Yoshida, K. & Ogawa, S. Splicing factor mutations and cancer. Wiley Interdiscip. Rev. RNA 5, 445\u2013459 (2014).","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"29777_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/ng.2523","volume":"45","author":"JW Harbour","year":"2013","unstructured":"Harbour, J. W. et al. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat. Genet. 45, 133 (2013).","journal-title":"Nat. Genet."},{"key":"29777_CR16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature11143","volume":"486","author":"MJ Ellis","year":"2012","unstructured":"Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353 (2012).","journal-title":"Nature"},{"key":"29777_CR17","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3390\/biom9100633","volume":"9","author":"J Bori\u0161ek","year":"2019","unstructured":"Bori\u0161ek, J. et al. Disclosing the impact of carcinogenic SF3b mutations on pre-mRNA recognition via all-atom simulations. Biomolecules 9, 633 (2019).","journal-title":"Biomolecules"},{"key":"29777_CR18","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12864-016-2727-x","volume":"17","author":"T Chen","year":"2016","unstructured":"Chen, T. et al. Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types. BMC Genomics 17, 394 (2016).","journal-title":"BMC Genomics"},{"key":"29777_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1006\/jsbi.2001.4392","volume":"134","author":"MA Andrade","year":"2001","unstructured":"Andrade, M. A., Perez-Iratxeta, C. & Ponting, C. P. Protein repeats: Structures, functions, and evolution. J. Struct. Biol. 134, 117\u2013131 (2001).","journal-title":"J. Struct. Biol."},{"key":"29777_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3816\/CBC.2003.n.032","volume":"4","author":"RE Smith","year":"2003","unstructured":"Smith, R. E. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the national surgical adjuvant breast and bowel project experience. Clin. Breast Cancer 4, 273\u2013279 (2003).","journal-title":"Clin. Breast Cancer"},{"key":"29777_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1517\/14728222.2011.645805","volume":"16","author":"L Santarpia","year":"2012","unstructured":"Santarpia, L., Lippman, S. M. & El-Naggar, A. K. Targeting the MAPK\u2013RAS\u2013RAF signaling pathway in cancer therapy. Expert. Opin. Ther. Targets 16, 103\u2013119 (2012).","journal-title":"Expert. Opin. Ther. Targets"},{"key":"29777_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fonc.2014.00064","volume":"4","author":"C Porta","year":"2014","unstructured":"Porta, C., Paglino, C. & Mosca, A. Targeting PI3K\/Akt\/mTOR signaling in cancer. Front. Oncol. 4, 64 (2014).","journal-title":"Front. Oncol."},{"key":"29777_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0929-6646(09)60051-6","volume":"108","author":"W-C Huang","year":"2009","unstructured":"Huang, W.-C. & Hung, M.-C. Induction of Akt activity by chemotherapy confers acquired resistance. J. Formos. Med. Assoc. 108, 180\u2013194 (2009).","journal-title":"J. Formos. Med. Assoc."},{"key":"29777_CR24","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1371\/journal.pbio.0040147","volume":"4","author":"MJ Hicks","year":"2006","unstructured":"Hicks, M. J., Yang, C.-R., Kotlajich, M. V. & Hertel, K. J. Linking splicing to Pol II transcription stabilizes pre-mRNAs and influences splicing patterns. PLoS Biol. 4, e147 (2006).","journal-title":"PLoS Biol."},{"key":"29777_CR25","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ccell.2016.08.006","volume":"30","author":"EA Obeng","year":"2016","unstructured":"Obeng, E. A. et al. Physiologic expression of sf3b1k700e causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation. Cancer Cell 30, 404\u2013417 (2016).","journal-title":"Cancer Cell"},{"key":"29777_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nm.4493","volume":"24","author":"M Seiler","year":"2018","unstructured":"Seiler, M. et al. H3b\u20138800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat. Med. 24, 497\u2013504 (2018).","journal-title":"Nat. Med."},{"key":"29777_CR27","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/j.chembiol.2021.04.018","volume":"28","author":"RA Gama-Brambila","year":"2021","unstructured":"Gama-Brambila, R. A. et al. A protac targets splicing factor 3b1. Cell Chem. Biol. 28, 1616\u20131627 (2021).","journal-title":"Cell Chem. Biol."},{"key":"29777_CR28","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2018","unstructured":"Tate, J. G. et al. COSMIC: The catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941\u2013D947 (2018).","journal-title":"Nucleic Acids Res."},{"key":"29777_CR29","doi-asserted-by":"publisher","first-page":"D786","DOI":"10.1093\/nar\/gky930","volume":"47","author":"B Braschi","year":"2018","unstructured":"Braschi, B. et al. Genenames.org: The HGNC and VGNC resources in 2019. Nucleic Acids Res. 47, D786\u2013D792 (2018).","journal-title":"Nucleic Acids Res."},{"key":"29777_CR30","unstructured":"Piacentini, M. et al. DB browser for SQLite (2015)."},{"key":"29777_CR31","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"key":"29777_CR32","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/gb-2010-11-5-r53","volume":"11","author":"G Wu","year":"2010","unstructured":"Wu, G., Feng, X. & Stein, L. A human functional protein interaction network and its application to cancer data analysis. Genome Biol. 11, R53 (2010).","journal-title":"Genome Biol."},{"key":"29777_CR33","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1093\/bioinformatics\/btq538","volume":"26","author":"A Bauer-Mehren","year":"2010","unstructured":"Bauer-Mehren, A., Rautschka, M., Sanz, F. & Furlong, L. I. Disgenet: A cytoscape plugin to visualize, integrate, search and analyze gene\u2013disease networks. Bioinformatics 26, 2924\u20132926 (2010).","journal-title":"Bioinformatics"},{"key":"29777_CR34","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/bioinformatics\/btm554","volume":"24","author":"Y Assenov","year":"2007","unstructured":"Assenov, Y., Ram\u00edrez, F., Schelhorn, S.-E., Lengauer, T. & Albrecht, M. Computing topological parameters of biological networks. Bioinformatics 24, 282\u2013284 (2007).","journal-title":"Bioinformatics"},{"issue":"D1","key":"29777_CR35","doi-asserted-by":"publisher","first-page":"D845","DOI":"10.1093\/nar\/gkz1021","volume":"48","author":"J Pi\u00f1ero","year":"1999","unstructured":"Pi\u00f1ero, J. et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 48(D1), D845\u2013D855. https:\/\/doi.org\/10.1093\/nar\/gkz1021 (2020).","journal-title":"Nucleic Acids Res."},{"key":"29777_CR36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0959-440X(99)80052-9","volume":"9","author":"MR Groves","year":"1999","unstructured":"Groves, M. R. & Barford, D. Topological characteristics of helical repeat protein. Curr. Opin. Struct. Biol. 9, 383\u2013389 (1999).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"29777_CR37","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1093\/nar\/gkv312","volume":"43","author":"F Sadeghifar","year":"2015","unstructured":"Sadeghifar, F., B\u00f6hm, S., Vintermist, A. & \u00d6stlundFarrants, A.-K. The B-WICH chromatin-remodelling complex regulates RNA polymerase III transcription by promoting Max-dependent c-Myc binding. Nucleic Acids Res. 43, 4477\u20134490 (2015).","journal-title":"Nucleic Acids Res."},{"key":"29777_CR38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/cr.2018.14","volume":"28","author":"X Zhang","year":"2018","unstructured":"Zhang, X. et al. Structure of the human activated spliceosome in three conformational states. Cell Res. 28, 307 (2018).","journal-title":"Cell Res."},{"key":"29777_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1242\/dmm.000331","volume":"1","author":"JD Fackenthal","year":"2008","unstructured":"Fackenthal, J. D. & Godley, L. A. Aberrant RNA splicing and its functional consequences in cancer cells. Dis. Model. Mech. 1, 37\u201342 (2008).","journal-title":"Dis. Model. Mech."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29777-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29777-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29777-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T06:55:19Z","timestamp":1676962519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29777-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["29777"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-29777-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"assertion":[{"value":"4 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2704"}}